Lonza Group AG

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:30:49 2024-04-23 am EDT			5-day change	1st Jan Change
526.4 ^CHF	+3.87%		+0.04%	+48.83%

Apr. 18	Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...
Apr. 18	Lonza Finance Launches EUR1 Billion 12-Year Euro Bond	DJ

Lonza : Switzerland's Lonza to boost production for Moderna COVID-19 vaccine

April 29, 2021 at 01:07 am EDT

ZURICH, April 29 (Reuters) - Contract drug manufacturer Lonza plans to double Swiss production capacity for Moderna's COVID-19 vaccine, helping the U.S. drugmaker boost total output to as many as 3 billion doses in 2022. (Reporting by John Miller Editing by Riham Alkousaa)

Latest news about Lonza Group AG

Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	Apr. 18
Lonza Finance Launches EUR1 Billion 12-Year Euro Bond	Apr. 18	DJ
Switzerland's Lonza Group Prices EUR1 Billion Bond	Apr. 18	MT
NeuroSense Therapeutics Ltd. Collaborates with Lonza to Identify Exosome-Based Biomarkers, in Order to Advance Neurodegenerative Disease Treatments and Diagnostics	Apr. 09	CI
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	Apr. 04	MT
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	Apr. 04	CI
Health Care Down on Flight From Risk -- Health Care Roundup	Apr. 02	DJ
Indices: Five Magnificents instead of Seven	Apr. 02
Global markets live: UBS, AT&T, Tesla, United Airlines, Humana, Wanda...	Apr. 02
European Midday Briefing : Stocks Gain as Bonds Track Treasuries Lower	Apr. 02	DJ
Lonza Group Appoints New CEO; Seeks Lifting of Trading Halt	Apr. 02	MT
Lonza Taps Siegfried Holding's Wolfgang Wienand as Next CEO	Apr. 02	DJ
Siegfried CEO Steps Down; Finance Chief Named Interim CEO	Apr. 02	MT
Lonza Group Poaches Siegfried's CEO	Apr. 02	MT
Lonza Group AG Announces Chief Executive Officer Changes	Apr. 02	CI
Global markets live: Super Micro Computer, Boeing, Vale, Tesla, Nvidia, Intel, Nasdaq...	Mar. 20
Transcript : Lonza Group AG - Special Call	Mar. 20
Singaporean Shares Rise Tracking Global Gains; Top Glove’s Shares Up 9% as Losses Shrink	Mar. 20	MT
Lonza Shares Jump on U.S. Manufacturing Facility Buy From Roche	Mar. 20	DJ
Luxury stocks drag European equities lower ahead of Fed meeting	Mar. 20	RE
Lonza Group to Acquire Biologics Site in US for $1.2 billion	Mar. 20	MT
Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Billion	Mar. 20	DJ
Lonza to Buy US Biologics Manufacturing Site from Roche for $1.2 Billion	Mar. 20	MT
Lonza to buy biologics site from Roche in US for $1.2 bln	Mar. 20	RE
Lonza to acquire biologics site from Roche in U.S. for $1.2 billion	Mar. 20	RE

Chart Lonza Group AG

Duration

Period

More charts

Company Profile

Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Annual General Meeting

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

LONZA GROUP : Some mixed real-world effects

February 06, 2024 at 10:44 am EST

More Strategies

Ratings for Lonza Group AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

506.8 CHF

Average target price

566 CHF

Spread / Average Target

+11.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LONZA GROUP AG	+48.83%	40.08B
IQVIA HOLDINGS INC.	+1.96%	42.11B
MODERNA, INC.	+7.74%	40B
CELLTRION, INC.	-10.82%	26.87B
ICON PUBLIC LIMITED COMPANY	+7.92%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.38%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.73%	11.94B
MEDPACE HOLDINGS, INC.	+31.03%	11.66B
UNITED THERAPEUTICS CORPORATION	+7.23%	11.01B
BIO-TECHNE CORPORATION	-16.95%	9.87B

Other Biotechnology & Medical Research